Clinical trials: Lung Malignancy
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Asthma
Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years
A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FLUTIFORM® pMDI (2 puffs bid) vs Seretide® pMDI (2 puffs bid) in subjects aged ≥12 years with moderate to…
- Trial name
- NCT03387241
- Testing
- Fluticasone/ Formoterol, fluticasone/ salmeterol
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Non Small Cell Lung Cancer
Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano (IN.ON.D.)
According to an analysis by Memorial Sloan Kettering Cancer Center patients who receive a target therapy having an oncogenic driver mutation live longer than those who do not receive it.
- Trial name
- INOND (NCT06180005)
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Intubation; Difficult or Failed, Pediatric ALL
An Endotracheal Tube Inserted to the Level of the Hypopharynx
The goal of this observational study is to assess the incidence of successful ventilation using an ETT inserted orally above the vocal cords in pediatric patients undergoing surgeries.
- Conditions
- Intubation; Difficult or Failed, Pediatric ALL, Ventilator Lung
- Trial name
- NCT06449924
- Testing
- Endotracheal tube
- Where
- Lebanon
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- American University of Beirut Medical Center
Nonsmall Cell Lung Cancer
CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology
Lung cancer remains the leading cause of cancer related mortality worldwide, with more than 1.5 million related deaths annually.
- Trial name
- NCT03940846
- Testing
- Virtual biopsy
- Where
- Netherlands
- Volunteers
- 650 people
- Sponsor
- Maastricht University
Carcinoma, Non-Small-Cell Lung
Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer
Objective: L-[3-18F]-α-methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT00464282
- Sponsor
- Gunma University
Pulmonary Sarcoidosis
Treatment of Pulmonary Sarcoidosis With Pentoxifylline
Sarcoidosis is a disease most commonly affecting the lungs, but it can also involve lymph nodes, skin, liver, spleen, eyes, bones, and glands. The cause of the disease is unknown.
- Trial name
- NCT00001877
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms, Colonic Neoplasms
A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
This is a phase II clinical and pharmacokinetic study of suppression of human antimouse (HAMA) and antitoxin antibodies (HATA) to immunotoxin LMB-1 by Rituximab (anti-CD20).
- Conditions
- Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT00001805
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer Adenocarcinoma, Lung Cancer Squamous Cell
Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
Lung carcinoma is the second most common cancer and a leading cause of cancer-related mortality worldwide. In Egypt, lung carcinoma ranks the 5th among all cancer cases.
- Conditions
- Lung Cancer Adenocarcinoma, Lung Cancer Squamous Cell, Mesothelioma; Lung
- Trial name
- NCT05228795
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Chronic Myelogenous Leukemia
Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib
There is no available data on the clinical benefit of dose escalation for patients with suboptimal response to imatinib, and patients may still improve their response with continuation of therapy at the standard dose as shown in…
- Trial name
- LASOR (NCT00802841)
- Testing
- nilotinib, imatinib
- Where
- 56 sites in Argentina, Brazil and 10 more
- Volunteers
- 191 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Solid Tumor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of…
- Conditions
- Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer
- Trial name
- NCT07121829
- Testing
- Tovorafenib, Tovorafenib Drug: Pimasertib
- Where
- 10 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Lung Cancer (NSCLC)
easyEndoTM Powered in Thoracic Surgery
The goal of this retrospective, single-arm is to evaluate the safety and performance of the easyEndo™ Powered Single Use Powered Endoscopic Staplers and Cartridges in thoracic surgery.
- Trial name
- NCT07353489
- Testing
- easyEndoTM Powered Single Use Powered Endoscopic Staplers and Cartridges
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Ezisurg Medical Co. Ltd.
Lung Cancer (Diagnosis), Sarcoidosis
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).
- Conditions
- Lung Cancer (Diagnosis), Sarcoidosis, Chronic Obstructive Pulmonary Disease, Immunotherapy Resistance
- Trial name
- IMMUNOPUMON2 (NCT07384897)
- Testing
- Peripheral Blood Collection for Immune Profiling
- Where
- Belgium
- Volunteers
- 425 people, healthy volunteers welcome
- Sponsor
- Université Catholique de Louvain
Sepsis, Cancer, Heart Attack, Heart Failure, Abdominal Surgery, Trauma, Diabetes, Lung Disease, Gynaecology, Fertility, Cardiac Surgery,
Medical Record Study on Adverse Events Requiring a Higher Level of Care in Flemish Hospitals
An adverse event (AE) is defined as unintended injury or complication, which results in disability, death or prolongation of hospital stay, and is caused by healthcare management (including omissions) rather than the patient's…
- Trial name
- NCT02044718
- Where
- Belgium
- Volunteers
- 878 people
- Sponsor
- Hasselt University
Lung Cancer, Small Cell Lung Cancer
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma
- Trial name
- NCT05337163
- Testing
- Diagnostic Test: Sputum DNA methylation analysis, chest CT or pathological examination
- Where
- China
- Volunteers
- 1,564 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Malignant Mesothelioma
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Current therapies for advanced Mesothelioma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Mesothelioma.
- Trial name
- NCT00003508
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Burzynski Research Institute
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Osteosarcoma Metastatic, Pulmonary Disease
Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study
According to EURAMOS-1, 17% of osteosarcoma patients were considered to have metastases at diagnosis. In this selected cohort, the reported 5-year EFS from diagnosis of 28% compares well to previous results reported from…
- Conditions
- Osteosarcoma Metastatic, Pulmonary Disease, Resectable Sarcoma, Survival
- Trial name
- NCT04546243
- Testing
- resection group, radiotherapy group
- Where
- 2 sites in China
- Volunteers
- 127 people
- Sponsor
- Peking University People's Hospital
Carcinoma, Non-Small-Cell Lung
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
To collect information of safety in patients with unresectable advanced or recurrent non-small cell lung cancer who receive combination therapy of IMJUDO, IMFINZI and other platinum-based anti-cancer agents under actual use in…
- Trial name
- NCT05826366
- Where
- 28 sites in Japan
- Volunteers
- 296 people
- Sponsor
- AstraZeneca